{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:45:11Z","timestamp":1790196311171,"version":"4.1.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018956","name":"NIHR Cambridge Biomedical Research Centre","doi-asserted-by":"publisher","award":["BRC-1215-20014"],"award-info":[{"award-number":["BRC-1215-20014"]}],"id":[{"id":"10.13039\/501100018956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.berh.2021.101693","type":"journal-article","created":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T03:08:09Z","timestamp":1622862489000},"page":"101693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Unmet needs in psoriatic arthritis"],"prefix":"10.1016","volume":"35","author":[{"given":"Beverly Cheok Kuan","family":"NG","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak Rohit","family":"Jadon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.berh.2021.101693_bib1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/BOR.0000000000000152","article-title":"Recognizing and manging comorbidities in psoriatic arthritis","volume":"27","author":"Ogdie","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.berh.2021.101693_bib2","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/539683","article-title":"The Th17\/IL-23 Axis and natural immunity in psoriatic arthritis","author":"Maeda","year":"2012","journal-title":"Int J Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2021.101693_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.berh.2021.101693_bib4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jaad.2015.05.001","article-title":"Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis","volume":"73","author":"Villani","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.berh.2021.101693_bib5","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/rheumatology\/keg217","article-title":"Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study","volume":"42","author":"McHugh","year":"2003","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.berh.2021.101693_bib6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3899\/jrheum.190677","article-title":"Prevalence of psoriatic arthritis patients achieving minimal disease activity in real-life studies and randomized clinical trials: systematic review with meta-analysis","volume":"47","author":"Zardin-Moraes","year":"2019","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2021.101693_bib7","series-title":"BEST (biomarkers, EndpointS, and other tools) resource","year":"2016"},{"key":"10.1016\/j.berh.2021.101693_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3899\/jrheum.190118","article-title":"Proceedings of the 2018 GRAPPA collaborative research Network meeting","volume":"95","author":"Jadon","year":"2019","journal-title":"J\u00a0Rheumatol Suppl"},{"key":"10.1016\/j.berh.2021.101693_bib9","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","article-title":"Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis","volume":"74","author":"Haroon","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2021.101693_bib10","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2021.101693_bib11","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1002\/art.34536","article-title":"Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis","volume":"64","author":"Coates","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2021.101693_bib12","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/bjd.18227","article-title":"Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis","volume":"182","author":"Green","year":"2020","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.berh.2021.101693_bib13","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/bjd.12190","article-title":"Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study)","volume":"168","author":"Coates","year":"2013","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.berh.2021.101693_bib14","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1007\/s10067-018-4238-4","article-title":"Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: two-year clinical experience of a dermo-rheumatologic clinic","volume":"37","author":"Luchetti","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2021.101693_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-017-0706-0","article-title":"Early recognition and treatment heralds optimal outcomes: the benefits of combined rheumatology-dermatology clinics and integrative care of psoriasis and psoriatic arthritis patients","volume":"20","author":"Soleymani","year":"2017","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"10.1016\/j.berh.2021.101693_bib16","first-page":"675","article-title":"Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model","volume":"22","author":"Gladman","year":"1995","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2021.101693_bib17","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101693_bib18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/ard.2011.155044","article-title":"Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis","volume":"71","author":"Eder","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101693_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.clim.2016.07.019","article-title":"Implications of the diversity of class I HLA associations in psoriatic arthritis","volume":"172","author":"Winchester","year":"2016","journal-title":"Clin Immunol"},{"issue":"3","key":"10.1016\/j.berh.2021.101693_bib20","first-page":"586","article-title":"HLA antigens in psoriatic arthritis","volume":"13","author":"Gladman","year":"1986","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2021.101693_bib21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/rheumatology\/kev296","article-title":"HLA-B27 and psoriatic disease: a modern view of an old relationship","volume":"55","author":"Queiro","year":"2016","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.berh.2021.101693_bib22","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ajhg.2015.10.019","article-title":"Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture","volume":"97","author":"Stuart","year":"2015","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.berh.2021.101693_bib23","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1038\/s41467-018-06672-6","article-title":"Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients","volume":"9","author":"Patrick","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.berh.2021.101693_bib24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3899\/jrheum.140223","article-title":"Serum soluble bone turnover biomarkers in psoriatic arthritis and psoriatic spondyloarthropathy","volume":"42","author":"Jadon","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2021.101693_bib25","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/rheumatology\/keq105","article-title":"Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis with arthritis","volume":"49","author":"Chandran","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2021.101693_bib26","doi-asserted-by":"crossref","first-page":"R164","DOI":"10.1186\/ar3123","article-title":"Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion","volume":"12","author":"Dalbeth","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2021.101693_bib27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13075-017-1417-7","article-title":"Serum bone-turnover biomarkers are associated with the occurrence of peripheral and axial arthritis in psoriatic disease: a prospective cross-sectional comparative study","volume":"19","author":"Jadon","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.berh.2021.101693_bib28","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1002\/art.22843","article-title":"Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy","volume":"56","author":"Mullan","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2021.101693_bib29","doi-asserted-by":"crossref","first-page":"13541","DOI":"10.1038\/s41598-020-70327-0","article-title":"A\u00a0novel biomarker of MMP-cleaved prolargin is elevated in patients with psoriatic arthritis","volume":"10","author":"Sinkeviciute","year":"2020","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.berh.2021.101693_bib30","doi-asserted-by":"crossref","first-page":"R113","DOI":"10.1186\/ar3049","article-title":"Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT","volume":"12","author":"Gladman","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2021.101693_bib31","first-page":"2089","article-title":"S100 proteins calprotectin and S100A12 are related to radiographic changes rather than disease activity in psoriatic arthritis with low disease activity","volume":"34","author":"Madland","year":"2007","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2021.101693_bib32","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/art.33455","article-title":"Acute-phase serum amyloid A regulates tumor necrosis factor \u03b1 and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy","volume":"64","author":"Connolly","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2021.101693_bib33","first-page":"120","article-title":"Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis?","volume":"27","author":"Alenius","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2021.101693_bib34","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1002\/art.39800","article-title":"Brief report: CXCL10 is a possible biomarker for the development of psoriatic arthritis among patients with psoriasis","volume":"68","author":"Abji","year":"2016","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2021.101693_bib35","first-page":"665","article-title":"Differential expression of proteins with heparin affinity in patients with rheumatoid and psoriatic arthritis: a preliminary study","volume":"31","author":"Grazio","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2021.101693_bib36","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/MOG.0000000000000589","article-title":"Potentials of multiomics technology in precision medicine","volume":"35","author":"Putignani","year":"2019","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.berh.2021.101693_bib37","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1146\/annurev-immunol-042718-041841","article-title":"Gut microbiota regulation of T cells during inflammation and autoimmunity","volume":"37","author":"Brown","year":"2019","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"10.1016\/j.berh.2021.101693_bib38","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/art.38892","article-title":"Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease","volume":"67","author":"Scher","year":"2015","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2021.101693_bib39","first-page":"514","article-title":"Faecal microbiota transplantation for Clostridium difficile infection resulting in a decrease in psoriatic arthritis disease activity","volume":"37","author":"Selvanderan","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2021.101693_bib40","doi-asserted-by":"crossref","first-page":"248","DOI":"10.12688\/f1000research.4709.1","article-title":"Metabolomics in psoriatic disease: pilot study reveals metabolomic differences in psoriasis and psoriatic arthritis","volume":"3","author":"Armstrong","year":"2014","journal-title":"F1000 Res"},{"issue":"4","key":"10.1016\/j.berh.2021.101693_bib41","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2019-216374","article-title":"Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis","volume":"79","author":"Souto-Carneiro","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2021.101693_bib42","doi-asserted-by":"crossref","first-page":"R19","DOI":"10.1186\/ar3243","article-title":"Diagnostic properties of metabolic perturbations in rheumatoid arthritis","volume":"13","author":"Madsen","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"suppl10","key":"10.1016\/j.berh.2021.101693_bib43","first-page":"72","article-title":"Targeted metabolomic profiling and prediction of cardiovascular events: a prospective study of patients with psoriatic arthritis and psoriasis","author":"Colaco","year":"2020","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2021.101693_bib44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12916-016-0681-8","article-title":"Urine metabolome profiling of immune-mediated inflammatory diseases","volume":"14","author":"Alonso","year":"2016","journal-title":"BMC Med"},{"issue":"6","key":"10.1016\/j.berh.2021.101693_bib45","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/art.37921","article-title":"Metabolic profiling predicts response to anti-tumour necrosis factor \u03b1 therapy in patients with rheumatoid arthritis","volume":"65","author":"Kapoor","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.berh.2021.101693_bib46","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1080\/1744666X.2016.1193436","article-title":"Improvements in diagnostic tools for early detection of psoriatic arthritis","volume":"12","author":"D'Angelo","year":"2016","journal-title":"Expet Rev Clin Immunol"},{"key":"10.1016\/j.berh.2021.101693_bib47","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1093\/rheumatology\/ker078","article-title":"High prevalence of ultrasonographic synovitis and enthesopathy in patients with psoriasis without psoriatic arthritis: a prospective case-control study","volume":"50","author":"Naredo","year":"2011","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.berh.2021.101693_bib48","first-page":"159","article-title":"Ultrasonography in the early diagnosis of psoriatic associated enthesopathy","volume":"27","author":"De Filippis","year":"2005","journal-title":"Int J Tissue React"},{"key":"10.1016\/j.berh.2021.101693_bib49","first-page":"29","article-title":"Entheseal power Doppler ultrasonography: a comparison of psoriatic arthritis and fibromyalgia","volume":"89","author":"Marchesoni","year":"2012","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2021.101693_bib50","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000258049","article-title":"Role of contrast-enhanced ultrasound in early diagnosis of psoriatic arthritis","volume":"220","author":"Solivetti","year":"2010","journal-title":"Dermatology"},{"issue":"9","key":"10.1016\/j.berh.2021.101693_bib51","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/rheumatology\/kex179","article-title":"Musculoskeletal ultrasonography for psoriatic arthritis and psoriasis patients; a systematic literature review","volume":"56","author":"Zabotti","year":"2017","journal-title":"Rehumatol"},{"key":"10.1016\/j.berh.2021.101693_bib52","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3899\/jrheum.200128","article-title":"Development and validation of a sonographic enthesitis instrument in psoriatic arthritis: the GRAPPA diagnostic ultrasound enthesitis tool (DUET) project","volume":"96","author":"Eder","year":"2020","journal-title":"J\u00a0Rheumatol Suppl"},{"issue":"2","key":"10.1016\/j.berh.2021.101693_bib53","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/ar1934","article-title":"Magnetic resonance imaging in psoriatic arthritis: a review of the literature","volume":"8","author":"McQueen","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.berh.2021.101693_bib54","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1759720X10394031","article-title":"Recent advances in imaging in psoriatic arthritis","volume":"3","author":"Poggenborg","year":"2011","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"12","key":"10.1016\/j.berh.2021.101693_bib55","article-title":"Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis","volume":"47","author":"Chandran","year":"2010","journal-title":"J\u00a0Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2021.101693_bib56","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2021.101693_bib57","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/rheumatology\/keu415","article-title":"Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature","volume":"54","author":"Behrens","year":"2015","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.berh.2021.101693_bib58","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001047","article-title":"Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial","volume":"6","author":"Ducourau","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.berh.2021.101693_bib59","series-title":"Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis","first-page":"336","volume":"58","author":"Miyagawa","year":"2019"},{"issue":"1","key":"10.1016\/j.berh.2021.101693_bib60","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/rheumatology\/kel175","article-title":"The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients","volume":"46","author":"Seitz","year":"2007","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.berh.2021.101693_bib61","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1038\/jid.2014.123","article-title":"TNF-\u03b1 gene polymorphisms: association with disease susceptibility and response to anti-TNF-\u03b1 treatment in psoriatic arthritis","volume":"134","author":"Murdaca","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.berh.2021.101693_bib62","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jbspin.2012.02.003","article-title":"Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis","volume":"79","author":"Morales-Lara","year":"2012","journal-title":"Joint Bone Spine"},{"issue":"5","key":"10.1016\/j.berh.2021.101693_bib63","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3899\/jrheum.110980","article-title":"FCGR2A\/CD32A and FCGR3A\/CD16A variants and EULAR response to tumor necrosis factor-\u03b1 blockers in psoriatic arthritis: a longitudinal study with 6 Months of followup","volume":"39","author":"Ram\u00edrez","year":"2012","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2021.101693_bib64","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3899\/jrheum.121162","article-title":"Soluble biomarkers associated with response to treatment with tumour necrosis factor inhibitors in psoriatic arthritis","volume":"40","author":"Chandran","year":"2013","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2021.101693_bib65","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1136\/ard.2006.060079","article-title":"Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate","volume":"66","author":"Gratac\u00f3s","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101693_bib66","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3899\/jrheum.150744","article-title":"Effectiveness and feasibility associated with switching to a second or third TNF inhibitor in patients with psoriatic arthritis: a cohort study from southern Sweden","volume":"43","author":"Kristensen","year":"2016","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2021.101693_bib67","first-page":"23","article-title":"Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment","volume":"30","author":"Chimenti","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2021.101693_bib68","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/annrheumdis-2012-201697","article-title":"Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab","volume":"72","author":"Wagner","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101693_bib69","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/annrheumdis-2014-205417","article-title":"Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis","volume":"75","author":"Ademowo","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2021.101693_bib70","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/prca.201500051","article-title":"A\u00a0clinically based protein discovery strategy to identify potential biomarkers of response to anti-TNF-\u03b1 treatment of psoriatic arthritis","volume":"10","author":"Collins","year":"2016","journal-title":"Proteonomics Clin Appl"},{"key":"10.1016\/j.berh.2021.101693_bib71","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s40265-018-0994-3","article-title":"Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity","volume":"78","author":"Ye","year":"2018","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.berh.2021.101693_bib72","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-028517","volume":"9","author":"Uhrenholt","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.berh.2021.101693_bib73","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3899\/jrheum.110295","article-title":"Combination biologic treatment of refractory psoriasis and psoriatic arthritis","volume":"39","author":"Cuchacovich","year":"2012","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2021.101693_bib74","first-page":"1098","article-title":"Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center","volume":"12","author":"Heinecke","year":"2013","journal-title":"J\u00a0Drugs Dermatol JDD"},{"key":"10.1016\/j.berh.2021.101693_bib75","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdcr.2014.09.002","article-title":"Combined biologic therapy for the treatment of psoriasis and psoriatic arthritis: a case report","volume":"1","author":"Babalola","year":"2015","journal-title":"JAAD Case Reports"},{"key":"10.1016\/j.berh.2021.101693_bib76","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/bjd.14270","article-title":"Combination of antitumour necrosis factor-alpha and anti-interleukin-12\/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study","volume":"174","author":"Gniadecki","year":"2016","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.berh.2021.101693_bib77","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jdcr.2019.08.015","article-title":"Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis","volume":"5","author":"Thibodeaux","year":"2019","journal-title":"JAAD Case Reports"},{"issue":"11","key":"10.1016\/j.berh.2021.101693_bib78","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/art.40579","article-title":"Phase II study of ABT \u2013 122, a tumour necrosis factor \u2013 and interleukin-17a \u2013 targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate","volume":"70","author":"Mease","year":"2018","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.berh.2021.101693_bib79","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.cgh.2018.02.024","article-title":"Combining biologics in inflammatory bowel disease and other immune mediated inflammatory disorders","volume":"16","author":"Hirten","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.berh.2021.101693_bib80","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/rheumatology\/kel211","article-title":"Effective co-administration of infliximab and etanercept following the failure of sequential anti-TNF agents in a patient with HLA-b27-associated arthropathy","volume":"45","author":"Sheehy","year":"2006","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.berh.2021.101693_bib81","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3899\/jrheum.140021","article-title":"High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease","volume":"41","author":"Haroon","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2021.101693_bib82","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fimmu.2014.00368","article-title":"Relationships between adipose tissue and psoriasis, with or without arthritis","volume":"5","author":"Toussirot","year":"2014","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.berh.2021.101693_bib83","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/bjd.17741","article-title":"Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A Critically Appraised Topic","volume":"181","author":"Mahil","year":"2019","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.berh.2021.101693_bib84","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41584-019-0336-1","article-title":"Changing health behaviours in rheumatology: an introduction to behavioural economics","volume":"16","author":"Ogdie","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2021.101693_bib85","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10067-019-04734-8","article-title":"Systematic review of mental health comorbidities in psoriatic arthritis","volume":"39","author":"Zhao","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2021.101693_bib86","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20970028","article-title":"Depression in patients with spondyloarthritis: prevalence, incidence, risk factors, mechanisms and management","volume":"12","author":"Parkinson","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"3","key":"10.1016\/j.berh.2021.101693_bib87","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","article-title":"The psychosocial burden of psoriatic arthritis","volume":"47","author":"Husni","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2021.101693_bib88","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/rheumatology\/keaa298","article-title":"A\u00a0clinical and radiographic comparison of patients with psoriatic arthritis from different ethnic backgrounds","volume":"60","author":"Aslam","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2021.101693_bib89","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10067-016-3460-1","article-title":"Effect of ethnicity on disease activity and physical function in psoriatic arthritis in a multiethnic Asian population","volume":"36","author":"Leung","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2021.101693_bib90","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11926-018-0785-6","article-title":"Bridging the gaps in the care of psoriasis and psoriatic arthritis: the role of combined clinics","volume":"20","author":"Haberman","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.berh.2021.101693_bib91","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11926-019-0876-z","article-title":"Strategies to improve outcomes in psoriatic arthritis","volume":"21","author":"Ritchlin","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.berh.2021.101693_bib92","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1046\/j.1365-2133.2002.04622.x","article-title":"A\u00a0cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy","volume":"146","author":"Fortune","year":"2002","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.berh.2021.101693_bib93","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/jdv.13306","article-title":"Promoting patient-centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the experience","volume":"30","author":"Betteridge","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.berh.2021.101693_bib94","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20951733","article-title":"Uveitis in spondyloarthritis","volume":"12","author":"Rademacher","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.berh.2021.101693_bib95","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20939410","article-title":"IBD considerations in spondyloarthritis","volume":"12","author":"Di Jiang","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"suppl10","key":"10.1016\/j.berh.2021.101693_bib96","article-title":"Can a clinical disease activity index based on patient-reported joint counts (PT-CDAI) Be used to inform target-based care in telemedicine? An analysis of 2 early RA cohort studies","volume":"72","author":"Benson","year":"2020","journal-title":"Arthritis Rheum"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694221000358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694221000358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:21:50Z","timestamp":1761499310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694221000358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":96,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1521694221000358"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2021.101693","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unmet needs in psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2021.101693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2021 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101693"}}